Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 288

1.

Cross-reactive microbial peptides can modulate HIV-specific CD8+ T cell responses.

Pohlmeyer CW, Laskey SB, Beck SE, Xu DC, Capoferri AA, Garliss CC, May ME, Livingston A, Lichmira W, Moore RD, Leffell MS, Butler NJ, Thorne JE, Flynn JA, Siliciano RF, Blankson JN.

PLoS One. 2018 Feb 21;13(2):e0192098. doi: 10.1371/journal.pone.0192098. eCollection 2018.

2.

Measuring replication competent HIV-1: advances and challenges in defining the latent reservoir.

Wang Z, Simonetti FR, Siliciano RF, Laird GM.

Retrovirology. 2018 Feb 13;15(1):21. doi: 10.1186/s12977-018-0404-7. Review.

3.

Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells.

Huang SH, Ren Y, Thomas AS, Chan D, Mueller S, Ward AR, Patel S, Bollard CM, Cruz CR, Karandish S, Truong R, Macedo AB, Bosque A, Kovacs C, Benko E, Piechocka-Trocha A, Wong H, Jeng E, Nixon DF, Ho YC, Siliciano RF, Walker BD, Jones RB.

J Clin Invest. 2018 Feb 1;128(2):876-889. doi: 10.1172/JCI97555. Epub 2018 Jan 22.

4.

Re-evaluating evolution in the HIV reservoir.

Rosenbloom DIS, Hill AL, Laskey SB, Siliciano RF.

Nature. 2017 Nov 22;551(7681):E6-E9. doi: 10.1038/nature24634. No abstract available.

PMID:
29168805
5.

HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.

Henrich TJ, Hatano H, Bacon O, Hogan LE, Rutishauser R, Hill A, Kearney MF, Anderson EM, Buchbinder SP, Cohen SE, Abdel-Mohsen M, Pohlmeyer CW, Fromentin R, Hoh R, Liu AY, McCune JM, Spindler J, Metcalf-Pate K, Hobbs KS, Thanh C, Gibson EA, Kuritzkes DR, Siliciano RF, Price RW, Richman DD, Chomont N, Siliciano JD, Mellors JW, Yukl SA, Blankson JN, Liegler T, Deeks SG.

PLoS Med. 2017 Nov 7;14(11):e1002417. doi: 10.1371/journal.pmed.1002417. eCollection 2017 Nov.

6.

Assays to Measure Latency, Reservoirs, and Reactivation.

Siliciano JD, Siliciano RF.

Curr Top Microbiol Immunol. 2017 Oct 26. doi: 10.1007/82_2017_75. [Epub ahead of print]

PMID:
29071475
7.

Transcriptional Reprogramming during Effector-to-Memory Transition Renders CD4+ T Cells Permissive for Latent HIV-1 Infection.

Shan L, Deng K, Gao H, Xing S, Capoferri AA, Durand CM, Rabi SA, Laird GM, Kim M, Hosmane NN, Yang HC, Zhang H, Margolick JB, Li L, Cai W, Ke R, Flavell RA, Siliciano JD, Siliciano RF.

Immunity. 2017 Oct 17;47(4):766-775.e3. doi: 10.1016/j.immuni.2017.09.014.

PMID:
29045905
8.

Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV.

Hill AL, Rosenbloom DIS, Goldstein E, Hanhauser E, Kuritzkes DR, Siliciano RF, Henrich TJ.

PLoS Pathog. 2017 Jul 6;13(7):e1006488. doi: 10.1371/journal.ppat.1006488. eCollection 2017 Jul.

9.

HIV persistence: clonal expansion of cells in the latent reservoir.

Kwon KJ, Siliciano RF.

J Clin Invest. 2017 Jun 30;127(7):2536-2538. doi: 10.1172/JCI95329. Epub 2017 Jun 19.

10.

Reduced Frequency of Cells Latently Infected With Replication-Competent Human Immunodeficiency Virus-1 in Virally Suppressed Individuals Living in Rakai, Uganda.

Prodger JL, Lai J, Reynolds SJ, Keruly JC, Moore RD, Kasule J, Kityamuweesi T, Buule P, Serwadda D, Nason M, Capoferri AA, Porcella SF, Siliciano RF, Redd AD, Siliciano JD, Quinn TC.

Clin Infect Dis. 2017 Oct 15;65(8):1308-1315. doi: 10.1093/cid/cix478.

PMID:
28535179
11.

Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape.

Pollack RA, Jones RB, Pertea M, Bruner KM, Martin AR, Thomas AS, Capoferri AA, Beg SA, Huang SH, Karandish S, Hao H, Halper-Stromberg E, Yong PC, Kovacs C, Benko E, Siliciano RF, Ho YC.

Cell Host Microbe. 2017 Apr 12;21(4):494-506.e4. doi: 10.1016/j.chom.2017.03.008.

PMID:
28407485
12.

Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics.

Hosmane NN, Kwon KJ, Bruner KM, Capoferri AA, Beg S, Rosenbloom DI, Keele BF, Ho YC, Siliciano JD, Siliciano RF.

J Exp Med. 2017 Apr 3;214(4):959-972. doi: 10.1084/jem.20170193. Epub 2017 Mar 24.

13.

Corrigendum: Nuclear landscape of HIV-1 infection and integration.

Lusic M, Siliciano RF.

Nat Rev Microbiol. 2017 Feb 27. doi: 10.1038/nrmicro.2017.22. [Epub ahead of print] No abstract available.

PMID:
28239151
14.

Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity.

Martin AR, Pollack RA, Capoferri A, Ambinder RF, Durand CM, Siliciano RF.

J Clin Invest. 2017 Feb 1;127(2):651-656. doi: 10.1172/JCI89552. Epub 2017 Jan 17.

15.

The mTOR Complex Controls HIV Latency.

Besnard E, Hakre S, Kampmann M, Lim HW, Hosmane NN, Martin A, Bassik MC, Verschueren E, Battivelli E, Chan J, Svensson JP, Gramatica A, Conrad RJ, Ott M, Greene WC, Krogan NJ, Siliciano RF, Weissman JS, Verdin E.

Cell Host Microbe. 2016 Dec 14;20(6):785-797. doi: 10.1016/j.chom.2016.11.001.

16.

Nuclear landscape of HIV-1 infection and integration.

Lusic M, Siliciano RF.

Nat Rev Microbiol. 2017 Feb;15(2):69-82. doi: 10.1038/nrmicro.2016.162. Epub 2016 Dec 12. Review. Erratum in: Nat Rev Microbiol. 2017 Feb 27;:.

PMID:
27941817
17.

Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques.

Gama L, Abreu CM, Shirk EN, Price SL, Li M, Laird GM, Pate KA, Wietgrefe SW, O'Connor SL, Pianowski L, Haase AT, Van Lint C, Siliciano RF, Clements JE; LRA-SIV Study Group.

AIDS. 2017 Jan 2;31(1):5-14.

18.

Quantitative evaluation of the antiretroviral efficacy of dolutegravir.

Laskey SB, Siliciano RF.

JCI Insight. 2016 Nov 17;1(19):e90033.

19.

Insufficient Evidence for Rare Activation of Latent HIV in the Absence of Reservoir-Reducing Interventions.

Hill AL, Rosenbloom DI, Siliciano JD, Siliciano RF.

PLoS Pathog. 2016 Aug 25;12(8):e1005679. doi: 10.1371/journal.ppat.1005679. eCollection 2016 Aug. No abstract available.

20.

Defective proviruses rapidly accumulate during acute HIV-1 infection.

Bruner KM, Murray AJ, Pollack RA, Soliman MG, Laskey SB, Capoferri AA, Lai J, Strain MC, Lada SM, Hoh R, Ho YC, Richman DD, Deeks SG, Siliciano JD, Siliciano RF.

Nat Med. 2016 Sep;22(9):1043-9. doi: 10.1038/nm.4156. Epub 2016 Aug 8.

21.

Evaluating Clonal Expansion of HIV-Infected Cells: Optimization of PCR Strategies to Predict Clonality.

Laskey SB, Pohlmeyer CW, Bruner KM, Siliciano RF.

PLoS Pathog. 2016 Aug 5;12(8):e1005689. doi: 10.1371/journal.ppat.1005689. eCollection 2016 Aug.

22.

The Latent Reservoir for HIV-1: How Immunologic Memory and Clonal Expansion Contribute to HIV-1 Persistence.

Murray AJ, Kwon KJ, Farber DL, Siliciano RF.

J Immunol. 2016 Jul 15;197(2):407-17. doi: 10.4049/jimmunol.1600343. Review.

23.

Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV.

Hill AL, Rosenbloom DI, Goldstein E, Hanhauser E, Kuritzkes DR, Siliciano RF, Henrich TJ.

PLoS Pathog. 2016 Apr 27;12(4):e1005535. doi: 10.1371/journal.ppat.1005535. eCollection 2016 Apr. Erratum in: PLoS Pathog. 2016 Jul;12(7):e1005778. PLoS Pathog. 2017 Jul 6;13(7):e1006488.

24.

Genome editing for clinical HIV isolates.

Kim M, Siliciano RF.

Nat Biotechnol. 2016 Apr;34(4):388-9. doi: 10.1038/nbt.3531. No abstract available.

PMID:
27054991
25.

HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing Assay.

Sunshine S, Kirchner R, Amr SS, Mansur L, Shakhbatyan R, Kim M, Bosque A, Siliciano RF, Planelles V, Hofmann O, Ho Sui S, Li JZ.

J Virol. 2016 Apr 14;90(9):4511-9. doi: 10.1128/JVI.01617-15. Print 2016 May.

26.

Reservoir expansion by T-cell proliferation may be another barrier to curing HIV infection.

Kim M, Siliciano RF.

Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1692-4. doi: 10.1073/pnas.1600097113. Epub 2016 Feb 9. No abstract available.

27.

Recent developments in the effort to cure HIV infection: going beyond N = 1.

Siliciano JD, Siliciano RF.

J Clin Invest. 2016 Feb;126(2):409-14. doi: 10.1172/JCI86047. Epub 2016 Feb 1. Review.

28.

Measuring the Frequency of Latent HIV-1 in Resting CD4⁺ T Cells Using a Limiting Dilution Coculture Assay.

Laird GM, Rosenbloom DI, Lai J, Siliciano RF, Siliciano JD.

Methods Mol Biol. 2016;1354:239-53. doi: 10.1007/978-1-4939-3046-3_16.

PMID:
26714716
29.

HIV reservoirs: what, where and how to target them.

Churchill MJ, Deeks SG, Margolis DM, Siliciano RF, Swanstrom R.

Nat Rev Microbiol. 2016 Jan;14(1):55-60. doi: 10.1038/nrmicro.2015.5. Epub 2015 Nov 30. Review.

PMID:
26616417
30.

Progress Toward HIV Eradication: Case Reports, Current Efforts, and the Challenges Associated with Cure.

Martin AR, Siliciano RF.

Annu Rev Med. 2016;67:215-28. doi: 10.1146/annurev-med-011514-023043. Epub 2015 Nov 2. Review.

PMID:
26526767
31.

Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance.

Gray WT, Frey KM, Laskey SB, Mislak AC, Spasov KA, Lee WG, Bollini M, Siliciano RF, Jorgensen WL, Anderson KS.

ACS Med Chem Lett. 2015 Aug 31;6(10):1075-9. doi: 10.1021/acsmedchemlett.5b00254. eCollection 2015 Oct 8.

32.

Designing and Interpreting Limiting Dilution Assays: General Principles and Applications to the Latent Reservoir for Human Immunodeficiency Virus-1.

Rosenbloom DI, Elliott O, Hill AL, Henrich TJ, Siliciano JM, Siliciano RF.

Open Forum Infect Dis. 2015 Aug 26;2(4):ofv123. doi: 10.1093/ofid/ofv123. eCollection 2015 Dec. Review.

33.

Medroxyprogesterone acetate increases HIV-1 infection of unstimulated peripheral blood mononuclear cells in vitro.

Sampah ME, Laird GM, Blankson JN, Siliciano RF, Coleman JS.

AIDS. 2015 Jun 19;29(10):1137-46. doi: 10.1097/QAD.0000000000000681.

34.

Reply: To PMID 25117799.

Siliciano JD, Siliciano RF.

J Allergy Clin Immunol. 2015 Jul;136(1):214. doi: 10.1016/j.jaci.2015.03.044. Epub 2015 Jun 3. No abstract available.

PMID:
25979523
35.

The Remarkable Stability of the Latent Reservoir for HIV-1 in Resting Memory CD4+ T Cells.

Siliciano JM, Siliciano RF.

J Infect Dis. 2015 Nov 1;212(9):1345-7. doi: 10.1093/infdis/jiv219. Epub 2015 Apr 15. No abstract available.

PMID:
25877551
36.

Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.

Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, Durand CM, Siliciano JD, Siliciano RF.

J Clin Invest. 2015 May;125(5):1901-12. doi: 10.1172/JCI80142. Epub 2015 Mar 30.

37.

Towards an HIV-1 cure: measuring the latent reservoir.

Bruner KM, Hosmane NN, Siliciano RF.

Trends Microbiol. 2015 Apr;23(4):192-203. doi: 10.1016/j.tim.2015.01.013. Epub 2015 Mar 5. Review.

38.

HIV-1 integration landscape during latent and active infection.

Cohn LB, Silva IT, Oliveira TY, Rosales RA, Parrish EH, Learn GH, Hahn BH, Czartoski JL, McElrath MJ, Lehmann C, Klein F, Caskey M, Walker BD, Siliciano JD, Siliciano RF, Jankovic M, Nussenzweig MC.

Cell. 2015 Jan 29;160(3):420-32. doi: 10.1016/j.cell.2015.01.020.

39.

Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations.

Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, Lai J, McHugh HL, Hao H, Zhang H, Margolick JB, Gurer C, Murphy AJ, Valenzuela DM, Yancopoulos GD, Deeks SG, Strowig T, Kumar P, Siliciano JD, Salzberg SL, Flavell RA, Shan L, Siliciano RF.

Nature. 2015 Jan 15;517(7534):381-5. doi: 10.1038/nature14053. Epub 2015 Jan 7.

40.

A primary CD4(+) T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescence.

Kim M, Hosmane NN, Bullen CK, Capoferri A, Yang HC, Siliciano JD, Siliciano RF.

Nat Protoc. 2014 Dec;9(12):2755-70. doi: 10.1038/nprot.2014.188. Epub 2014 Nov 6.

41.

CD4+ and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cells.

Cockerham LR, Siliciano JD, Sinclair E, O'Doherty U, Palmer S, Yukl SA, Strain MC, Chomont N, Hecht FM, Siliciano RF, Richman DD, Deeks SG.

PLoS One. 2014 Oct 23;9(10):e110731. doi: 10.1371/journal.pone.0110731. eCollection 2014.

42.

Finding a cure for human immunodeficiency virus-1 infection.

Blankson JN, Siliciano JD, Siliciano RF.

Infect Dis Clin North Am. 2014 Dec;28(4):633-50. doi: 10.1016/j.idc.2014.08.007. Epub 2014 Sep 30. Review.

43.

A mechanistic theory to explain the efficacy of antiretroviral therapy.

Laskey SB, Siliciano RF.

Nat Rev Microbiol. 2014 Nov;12(11):772-80. doi: 10.1038/nrmicro3351. Epub 2014 Sep 29. Review.

PMID:
25263222
44.

AIDS/HIV. Rekindled HIV infection.

Siliciano JD, Siliciano RF.

Science. 2014 Aug 29;345(6200):1005-6. doi: 10.1126/science.1259452. No abstract available.

PMID:
25170139
45.

Recent developments in the search for a cure for HIV-1 infection: targeting the latent reservoir for HIV-1.

Siliciano JD, Siliciano RF.

J Allergy Clin Immunol. 2014 Jul;134(1):12-9. doi: 10.1016/j.jaci.2014.05.026. Epub 2014 Jun 26. Review.

PMID:
25117799
46.

Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1.

Hill AL, Rosenbloom DI, Fu F, Nowak MA, Siliciano RF.

Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13475-80. doi: 10.1073/pnas.1406663111. Epub 2014 Aug 5. Erratum in: Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15598.

47.

HIV: Early treatment may not be early enough.

Deng K, Siliciano RF.

Nature. 2014 Aug 7;512(7512):35-6. doi: 10.1038/nature13647. Epub 2014 Jul 20. No abstract available.

PMID:
25043038
48.

Screening for noise in gene expression identifies drug synergies.

Dar RD, Hosmane NN, Arkin MR, Siliciano RF, Weinberger LS.

Science. 2014 Jun 20;344(6190):1392-6. doi: 10.1126/science.1250220. Epub 2014 Jun 5.

49.

Unraveling the relationship between microbial translocation and systemic immune activation in HIV infection.

Shan L, Siliciano RF.

J Clin Invest. 2014 Jun;124(6):2368-71. doi: 10.1172/JCI75799. Epub 2014 May 16.

50.

Opening Fronts in HIV Vaccine Development: Targeting reservoirs to clear and cure.

Siliciano RF.

Nat Med. 2014 May;20(5):480-1. doi: 10.1038/nm.3550. No abstract available.

PMID:
24804757

Supplemental Content

Loading ...
Support Center